Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04706507 · ClinicalTrials.gov registry record · Phase 3
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
NCT04706507 is a Phase 3 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 205 participants.
The verdict
NCT04706507, a Phase 3 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
Study Summary
This is a phase 3 study designed to evaluate whether the administration of ganciclovir increases ventilator-free days in immunocompetent patients with sepsis associated acute respiratory failure. Our hypothesis is that IV ganciclovir administered early in critical illness will effectively suppress CMV reactivation in CMV seropositive adults with sepsis-associated acute respiratory failure thereby leading to improved clinical outcomes
Interventions
- DRUG Normal saline
- DRUG IV Ganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2025-04-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04706507
The ClinicalTrials.gov registry entry for NCT04706507 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 205 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal saline is the first listed.
NCT04706507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04706507 about?
NCT04706507 is a clinical study titled "Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis". This is a phase 3 study designed to evaluate whether the administration of ganciclovir increases ventilator-free days in immunocompetent patients with sepsis associated acute respiratory failure. Our hypothesis is that IV ganciclovir administered early in critical illness will effectively suppress C...
What is the current status of trial NCT04706507?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2021-06-29. Estimated completion is 2025-04-08.
What interventions are being tested in trial NCT04706507?
The interventions under investigation include: Normal saline (DRUG), IV Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT04706507?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.